Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: A study of 157 cases

Stroke

Volumn 35, Issue 6, 2004, Pages 1323-1328

  Trouillas, Paul ^a   Derex, Laurent ^a   Philippeau, Fréderic ^a,c   Nighoghossian, Norbert ^a   Honnorat, Jerome ^a   Hanss, Micel ^c   Ffrench, Patrick ^c   Adeleine, Patrice ^b   Dechavanne, Marc ^c  

^a HÔPITAL NEUROLOGIQUE   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c LOUIS PRADEL HOSPITAL   (France)

Author keywords

Fibrinogen; Fibrinogen degradation products; Hematoma; Hemorrhage; Thrombolysis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; FIBRIN; FIBRINOGEN DEGRADATION PRODUCT;

ADULT; AGED; ARTICLE; BIOLOGICAL MONITORING; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; BRAIN HEMATOMA; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EARLY FIBRINOGEN DEGRADATION COAGULOPATHY; FEMALE; FIBRINOGEN METABOLISM; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARAMETER; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; SYMPTOM;

CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HEMATOMA; HUMANS; PROGNOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 2542635149     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000126040.99024.cf     Document Type: Article

References (29)

1. The Multicentre Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-150.
2. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomised controlled trial. JAMA. 1999;282:2003-2011.
3. NINDS rt-PA Stroke Study Group. Tissue plasminogen for acute ischemic stroke. N Eng J Med. 1995;333:1581-1587.
4. Hacke W, Kaste, Fieschi C, Toni D, Lesaffre E, Von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, Hennerici M, for the ECASS Study Group. Intravenous thrombolysis with tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
5. Hacke W, Kaste, Fieschi C, Von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1250.
6. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999 Dec 1;282(21):2019-26.
7. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA for ischemic stroke. Stroke. 1997;28:2109-2118.
8. Larrue V, Von Kummer R, Del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28:586-590.
9. Larrue V, Von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438-441.
10. Berger C, Fiorelli M, Steiner T, Schäbitz WR, Bozzao L, Bluhmki E, Hacke, Von Kummer R. Hemorrhagic transformation of ischemic brain tissue. Asymptomatic or Symptomatic? Stroke. 2001;32:1330-1335.
11. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M, and the PROACT II investigators. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001;57:1603-1610.
12. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Kennedy R, Hommel M. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. Stroke. 1999;30:1326-1332.
13. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke. 2001;32:12-16.
14. Demchuk AM, Morgenstern LB, Krieger DW, Chi LT, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30:34-39.
15. Trouillas P, Nighoghossian N, Getenet JC, Riche G, Honnoral J, Neuschwander P, Froment JC, Turjman F, Jin JX, Malicier D, Fournier G, Gabry AL, Ledoux X, Derex L, Berthezène Y, Adeleine P, Xie J, Ffrench P, Dechavanne M. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlation of outcome with clinical and radiological data. Stroke. 1996;27:889-890.
16. Trouillas P, Nighoghossian N, Derex L, Adeleine P, Honnoral J, Neuschwander P, Riche G, Getenet JC, Weil L, Froment JC, Turjman F, Malicier D, Fournier G, Gabry AL, Ledoux X, Berthezène Y, Ffrench P, Dechavanne M. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke. Stroke. 1998;29:2529-2540.
17. Trouillas P, Philippeau F, Nighoghossian N, Derex L, Honnorat J, Dechavanne MA. Biological syndrome predictive of cerebral bleeding in rtPA thrombolysis (data from the Lyon Thrombolysis Registry) (9th European Stroke Conference, Vienna, 24-27 May 2000). Cerebrovasc Dis. 2000;10:71.
18. Fiorelli M, Bastianello S, Von Kummer R, Del Zoppo G, Larrue V, Lesaffre E, Ringleb AP, Lorenzano S, Manelfe C, Bozzao L, for the ECASS I Study Group. Hemorrhagic transformation within 36 hours of a cerebral infarct. Relationship with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30:2280-2284.
19. Rao AK, Pratt C, Breke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI investigators. Thrombolysis In Myocardial Infarction (TIMI) trial-Phase I. hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
20. Mueller HS, Rao AK, Forman SA. Thrombolysis In Myocardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1987;10:479-490.
21. Arnold AE, Brower RW, Collen D, Van Es GA, Lubsen J, Serruys PW, Simoons ML, Verstraete M, for the European Cooperative Study Group for rt-PA. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. J Am Coll Cardiol. 1989;14:581-588.
22. Kase CK, Pessin MS, Zivin JA, Del Zoppo GJ, Furlan AJ, Buckley JW, Snipes RJ, Littlejohn JK. Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. JAMA. 1992;92:384-390.
23. Gore JM, Sloan M, Price TR, Randall AMY, Bovill E, Collen D, Forman S, Knatterud GL, Soppko G, Terrin ML, and the TIMI Investigators. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Thrombolysis in Myocardial Infarction, phase II pilot and clinical trial. Circulation. 21991;83:448-459.
24. Gebel JM, Sila CA, Sloan MA, Granger CB, Mahaffey KW, Weisenberger J, Green CL, White HD, Gore JM, Weaver WD, Califf RM, Topol EJ, for the GUSTO-1 Investigators. Thrombolysis-related intracranial hemorrhage. A radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Stroke. 1998;29:563-569.
25. Declerck P, Mombaerts P, Holvoet P, Collen D. Plasma levels of fragment D-dimer of cross-linked fibrin during thrombolytic therapy with recombinant tissue-type plasminogen activator. Thromb Hemost. 1987:58;231. Abstract.
26. Collen D, Bounameaux H, De Cock F, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation. 1986;73:511-517.
27. Wintrobe MM, Lee GR, Bogs DR, et al. Clinical Hematology. 8th ed. Philadelphia, Pa: Lea and Febiger; 1981:434.
28. Fassbender k, Dempfle CE, Mielke O, Schwartz A, Daffertshofer M, Eschenfelder C, Dollman M, Hennerici M. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant plasminogen activator. Stroke. 1999;30:2101-2104.
29. Granger CB, Hirsch J, Califf RM, Col J, White HD, Bertriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ, for the GUSTO-I investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarct. Results from the GUSTO-I trial. Circulation. 1996;93:870-878.